Nicholas Lydon - Net Worth and Insider Trading
Nicholas Lydon Net Worth
The estimated net worth of Nicholas Lydon is at least $10 Million dollars as of 2024-05-12. Nicholas Lydon is the Director of AnaptysBio Inc and owns about 271,106 shares of AnaptysBio Inc (ANAB) stock worth over $6 Million. Nicholas Lydon is also the Director of Blueprint Medicines Corp and owns about 37,425 shares of Blueprint Medicines Corp (BPMC) stock worth over $4 Million. Details can be seen in Nicholas Lydon's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Nicholas Lydon has not made any transactions after 2020-10-01 and currently still holds the listed stock(s).
Transaction Summary of Nicholas Lydon
Nicholas Lydon Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Nicholas Lydon owns 2 companies in total, including Blueprint Medicines Corp (BPMC) , and AnaptysBio Inc (ANAB) .
Click here to see the complete history of Nicholas Lydon’s form 4 insider trades.
Insider Ownership Summary of Nicholas Lydon
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BPMC | Blueprint Medicines Corp | 2020-10-01 | director |
| ANAB | AnaptysBio Inc | 2018-04-16 | director |
Nicholas Lydon Latest Holdings Summary
Nicholas Lydon currently owns a total of 2 stocks. Among these stocks, Nicholas Lydon owns 271,106 shares of AnaptysBio Inc (ANAB) as of April 16, 2018, with a value of $6 Million and a weighting of 61.38%. Nicholas Lydon also owns 37,425 shares of Blueprint Medicines Corp (BPMC) as of October 1, 2020, with a value of $4 Million and a weighting of 38.62%.
Latest Holdings of Nicholas Lydon
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ANAB | AnaptysBio Inc | 2018-04-16 | 271,106 | 23.41 | 6,346,591 |
| BPMC | Blueprint Medicines Corp | 2020-10-01 | 37,425 | 106.70 | 3,993,248 |
Holding Weightings of Nicholas Lydon
Nicholas Lydon Form 4 Trading Tracker
According to the SEC Form 4 filings, Nicholas Lydon has made a total of 0 transactions in AnaptysBio Inc (ANAB) over the past 5 years. The most-recent trade in AnaptysBio Inc is the sale of 33,000 shares on April 16, 2018, which brought Nicholas Lydon around $3 Million.
According to the SEC Form 4 filings, Nicholas Lydon has made a total of 8 transactions in Blueprint Medicines Corp (BPMC) over the past 5 years, including 0 buys and 8 sells. The most-recent trade in Blueprint Medicines Corp is the sale of 9,815 shares on October 1, 2020, which brought Nicholas Lydon around $913,580.
Insider Trading History of Nicholas Lydon
- 1
Nicholas Lydon Trading Performance
GuruFocus tracks the stock performance after each of Nicholas Lydon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Nicholas Lydon is 54.69%. GuruFocus also compares Nicholas Lydon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Nicholas Lydon within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Nicholas Lydon's insider trading performs compared to the benchmark.
Performance of Nicholas Lydon
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 33.69 | | | | | |
| Relative Return to S&P 500(%) | 29.12 | | | | | |
Nicholas Lydon Ownership Network
Nicholas Lydon Owned Company Details
What does Blueprint Medicines Corp do?
Who are the key executives at Blueprint Medicines Corp?
Nicholas Lydon is the director of Blueprint Medicines Corp. Other key executives at Blueprint Medicines Corp include Principal FAO Michael Landsittel , Principal Accounting Officer Ariel Hurley , and director & CEO & President Jeffrey W. Albers .
Blueprint Medicines Corp (BPMC) Insider Trades Summary
Over the past 18 months, Nicholas Lydon made no insider transaction in Blueprint Medicines Corp (BPMC). Other recent insider transactions involving Blueprint Medicines Corp (BPMC) include a net sale of 175,899 shares made by Jeffrey W. Albers , a net sale of 11,217 shares made by Christopher K. Murray , and a net sale of 36,744 shares made by Michael Landsittel .
In summary, during the past 3 months, insiders sold 130,368 shares of Blueprint Medicines Corp (BPMC) in total and bought 0 shares, with a net sale of 130,368 shares. During the past 18 months, 312,641 shares of Blueprint Medicines Corp (BPMC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 312,641 shares.
Blueprint Medicines Corp (BPMC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Blueprint Medicines Corp Insider Transactions
Nicholas Lydon Mailing Address
Above is the net worth, insider trading, and ownership report for Nicholas Lydon. You might contact Nicholas Lydon via mailing address: Blueprint Medicines Corp., 215 First Street, Suite 340/350, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
